P Greenberg

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
    P Greenberg
    VA Palo Alto Health Care System and Stanford University Medical Centre, CA 94305, USA
    Ann Rheum Dis 60:iii41-2. 2001
  2. ncbi request reprint Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)
    Peter L Greenberg
    Hematology Division, Stanford University Medical Center, 703 Welch Rd, Suite G 1, Stanford, CA 94305, USA
    J Clin Oncol 22:1078-86. 2004
  3. ncbi request reprint The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, California 94305 5821, USA
    J Natl Compr Canc Netw 11:877-84; quiz 885. 2013
  4. doi request reprint A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
    Leuk Lymphoma 54:321-8. 2013
  5. ncbi request reprint Revised international prognostic scoring system for myelodysplastic syndromes
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
    Blood 120:2454-65. 2012
  6. doi request reprint Molecular and genetic features of myelodysplastic syndromes
    P L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA, USA
    Int J Lab Hematol 34:215-22. 2012
  7. doi request reprint Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
    Peter L Greenberg
    Division of Hematology, Stanford University Cancer Center, Stanford, CA 94305, USA
    Leuk Res 34:1560-5. 2010
  8. doi request reprint Current therapeutic approaches for patients with myelodysplastic syndromes
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305 5821, USA
    Br J Haematol 150:131-43. 2010
  9. pmc Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
    Peter L Greenberg
    Stanford University Cancer Center, CA 94305, USA
    Blood 114:2393-400. 2009
  10. ncbi request reprint The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines
    Peter L Greenberg
    Stanford University Cancer Center, Stanford, California 94305 5821, USA
    J Natl Compr Canc Netw 6:942-53. 2008

Detail Information

Publications23

  1. pmc Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
    P Greenberg
    VA Palo Alto Health Care System and Stanford University Medical Centre, CA 94305, USA
    Ann Rheum Dis 60:iii41-2. 2001
    ..Further studies are warranted using anti-TNFalpha/anti-inhibitory cytokine approaches, either alone or in combination with other agents, capable of abrogating the effects of additional inhibitory mechanisms in MDS...
  2. ncbi request reprint Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)
    Peter L Greenberg
    Hematology Division, Stanford University Medical Center, 703 Welch Rd, Suite G 1, Stanford, CA 94305, USA
    J Clin Oncol 22:1078-86. 2004
    ....
  3. ncbi request reprint The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, California 94305 5821, USA
    J Natl Compr Canc Netw 11:877-84; quiz 885. 2013
    ..The discussion provides a synthesis of the prognostic clinical, molecular, and biologic abnormalities intrinsic to the aberrant marrow hematopoietic and microenvironmental influences in MDS. ..
  4. doi request reprint A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
    Leuk Lymphoma 54:321-8. 2013
    ....
  5. ncbi request reprint Revised international prognostic scoring system for myelodysplastic syndromes
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
    Blood 120:2454-65. 2012
    ..As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease...
  6. doi request reprint Molecular and genetic features of myelodysplastic syndromes
    P L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA, USA
    Int J Lab Hematol 34:215-22. 2012
    ..Use of more comprehensive and sensitive methods for molecular profiling using 'next-generation' sequencing techniques for MDS marrow cells will likely further define critical biologic lesions underlying this spectrum of diseases...
  7. doi request reprint Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
    Peter L Greenberg
    Division of Hematology, Stanford University Cancer Center, Stanford, CA 94305, USA
    Leuk Res 34:1560-5. 2010
    ....
  8. doi request reprint Current therapeutic approaches for patients with myelodysplastic syndromes
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305 5821, USA
    Br J Haematol 150:131-43. 2010
    ..The rationale for use of low versus high intensity therapies with these agents, including allogeneic haematopoietic stem cell transplantation, is discussed in detail...
  9. pmc Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
    Peter L Greenberg
    Stanford University Cancer Center, CA 94305, USA
    Blood 114:2393-400. 2009
    ..In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation...
  10. ncbi request reprint The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines
    Peter L Greenberg
    Stanford University Cancer Center, Stanford, California 94305 5821, USA
    J Natl Compr Canc Netw 6:942-53. 2008
    ..The economic impact of drug therapy should be weighed against the patient's potential for improvement in clinical outcomes, quality of life, and transfusion requirements...
  11. ncbi request reprint Myelodysplastic syndromes: iron overload consequences and current chelating therapies
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, 875 Blake Wilbur Drive, Room 2335, Stanford, CA 94305 5821, USA
    J Natl Compr Canc Netw 4:91-6. 2006
    ..These outcomes could potentially alter the tissue siderosis-associated morbidity of patients with MDS, particularly those with pre-existing cardiac disease...
  12. doi request reprint A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
    Jason Gotlib
    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
    Am J Hematol 84:15-20. 2009
    ..Our data indicate that weekly weight-based dosing of DA, with the addition of G-CSF in selected individuals, can be an effective erythropoietic option in a high proportion of lower-risk MDS patients...
  13. ncbi request reprint Myelodysplastic syndromes clinical practice guidelines in oncology
    Peter L Greenberg
    Stanford Hospital and Clinics, Stanford, CA, USA
    J Natl Compr Canc Netw 4:58-77. 2006
  14. ncbi request reprint Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study
    Athena M Cherry
    Department of Pathology, Stanford Hospital and Clinics, Stanford, CA 94305, USA
    Leuk Res 27:1085-90. 2003
    ..In addition, it appears that interphase FISH studies are nearly as sensitive as cytogenetic analyses and can be a useful tool in studying bone marrow aspirates where cytogenetic analysis is not possible...
  15. ncbi request reprint Management of patients with higher risk myelodysplastic syndromes
    Jon S Fukumoto
    Division of Hematology, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305 5821, USA
    Crit Rev Oncol Hematol 56:179-92. 2005
    ..This paper reviews the various therapeutic options for higher risk MDS, providing rationale for specific management approaches for these patients...
  16. doi request reprint International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes
    Jelena M Kao
    Division of Hematology, Stanford University Cancer Center, Stanford, California 94305 5821, USA
    Am J Hematol 83:765-70. 2008
    ..This information should prove useful for aiding therapeutic decision-making, prognostic classification, and designing clinical trials for patients with MDS...
  17. pmc Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
    Kunju Sridhar
    Hematology Division, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Blood 114:4847-58. 2009
    ....
  18. ncbi request reprint Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
    Azra Raza
    Rush University Medical Center, Chicago, IL, USA
    Blood 111:86-93. 2008
    ..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality...
  19. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    J Natl Compr Canc Netw 3:732-55. 2005
  20. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    University of Texas M D Anderson Cancer Center, USA
    J Natl Compr Canc Netw 5:474-96. 2007
  21. ncbi request reprint Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    Blood 108:419-25. 2006
    ..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
  22. pmc A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Blood 109:1387-94. 2007
    ..Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response...
  23. ncbi request reprint A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
    Blood 111:2589-96. 2008
    ..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...